serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
Published 2 years ago • 377 plays • Length 4:39Download video MP4
Download video MP3
Similar videos
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
1:39
clinical trials for stage ii-iii breast cancer
-
0:55
cambria-1: camizestrant vs standard endocrine therapy in breast cancer
-
56:42
research update for her2-positive mbc | 2021-2022 embrace mbc virtual forum series
-
3:13
ac versus taxac in high-risk her2-negative mbc
-
6:19
selecting agents in cdk4/6 inhibition for hr mbc
-
46:00
mbc online vet tech review 2.6 - endocrine system
-
59:41
persistent differentiated thyroid cancer sherman 08092011
-
11:22
choice of sapien vs. corevalve tavr
-
6:19
hr mbc: considering the data and potential of tesetaxel
-
2:35
what does the future hold for serds in er breast cancer?
-
4:05
sophia trial in r/r her2 mbc
-
14:00
expert answers to common questions for tailoring adc therapies across the her2 spectrum in metast...
-
2:35
lasofoxifene shows promise for women with esr1-mutated mbc
-
59:39
er-positive breast cancer: what's new in treatment and research at mbc patient forum 2019
-
6:57
her2climb and nala trials: r/r her2 mbc
-
1:01:28
integrative medicine for metastatic breast cancer | 2022-2023 embrace mbc virtual forum series
-
1:00:38
research update for er-positive mbc | 2021-2022 embrace mbc virtual forum series
-
7:17
abemaciclib for er mbc
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
1:00:05
clinical trials: what you need to know | 2021-2022 embrace mbc virtual forum series